-
Lithium chloride
- CAS:7447-41-8
- MW:42.39400
- MF:ClLi
Reported in EPA TSCA Inventory. EPA Genetic Toxicology Program.
Hazard Codes of Lithium chloride (CAS NO.7447-41-8):?F,Xn,C,Xi
Risk Statements: 11-36/37/38-35-10-19-63-20/21/22?
R11: Highly flammable.?
R36/37/38: Irritating to eyes, respiratory system and skin.?
R35: Causes severe burns.?
R10: Flammable.?
R19: May form explosive peroxides.?
R63: Possible risk of harm to the unborn child.?
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-36/37/39-16-45-33-29-22?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.?
S16: Keep away from sources of ignition.?
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)?
S33: Take precautionary measures against static discharges.?
S29: Do not empty into drains.?
S22: Do not breathe dust.
RIDADR: UN 2789 8/PG 2
WGK Germany: 1
RTECS: OJ5950000
F: 3-10
HazardClass: 8
PackingGroup: III
HS Code 28273980
Human poison by ingestion. Experimental poison by intravenous and intracerebral routes. Moderately toxic by subcutaneous and intraperitoneal routes. Experimental teratogenic and reproductive effects. Human systemic effects by ingestion: somnolence, tremors, nausea or vomiting. An eye and severe skin irritant. Human mutation data reported. Questionable carcinogen with experimental neoplastigenic data. This material has been recommended and used as a substitute for sodium chloride in “salt-free” diets, but cases have been reported in which the ingestion of lithium chloride has produced dizziness, ringing in the ears, visual disturbances, tremors, and mental confusion. In most cases, the symptoms disappeared when use was discontinued. Prolonged absorption may cause disturbed electrolyte balance, impaired renal function. Reaction is violent with BrF3. When heated to decomposition it emits toxic fumes of Cl?. Used for dehumidification in the air conditioning industry. Also used to obtain lithium metal. See also LITHIUM COMPOUNDS.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
bird - wild | LD50 | oral | 422mg/kg (422mg/kg) | ? | Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983. |
cat | LD50 | intraperitoneal | 492mg/kg (492mg/kg) | ? | Russian Pharmacology and Toxicology Vol. 42, Pg. 9, 1979. |
cat | LDLo | subcutaneous | 450mg/kg (450mg/kg) | ? | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. |
dog | LDLo | intravenous | 500mg/kg (500mg/kg) | BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS MUSCULOSKELETAL: OTHER CHANGES |
Journal of Pharmacology and Experimental Therapeutics. Vol. 100, Pg. 429, 1950. |
frog | LDLo | subcutaneous | 885mg/kg (885mg/kg) | ? | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935. |
guinea pig | LD50 | intraperitoneal | 624mg/kg (624mg/kg) | ? | "Spravochnik po Toksikologii i Gigienicheskim Normativam Vol. -, Pg. 157, 1999. |
guinea pig | LDLo | subcutaneous | 620mg/kg (620mg/kg) | ? | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. |
human | LDLo | oral | 200mg/kg/3D (200mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: MUSCLE WEAKNESS |
JAMA, Journal of the American Medical Association. Vol. 139, Pg. 688, 1949. |
human | TDLo | oral | 243mg/kg/13D (243mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR GASTROINTESTINAL: NAUSEA OR VOMITING |
JAMA, Journal of the American Medical Association. Vol. 139, Pg. 688, 1949. |
mouse | LD50 | intracrebral | 14040ug/kg (14.04mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 69, Pg. 75, 1973. |
mouse | LD50 | intraperitoneal | 600mg/kg (600mg/kg) | ? | Journal of Thermal Biology. Vol. 6, Pg. 87, 1981. |
mouse | LD50 | intravenous | 363mg/kg (363mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS BEHAVIORAL: ANTIPSYCHOTIC |
Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 413, 1973. |
mouse | LD50 | oral | 1165mg/kg (1165mg/kg) | ? | Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970. |
mouse | LD50 | subcutaneous | 738mg/kg (738mg/kg) | BEHAVIORAL: TREMOR MUSCULOSKELETAL: OTHER CHANGES |
Acta Pharmacologica et Toxicologica. Vol. 43, Pg. 51, 1978. |
pigeon | LDLo | subcutaneous | 513mg/kg (513mg/kg) | ? | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935. |
quail | LD50 | oral | 422mg/kg (422mg/kg) | ? | Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983. |
rabbit | LD50 | oral | 800mg/kg (800mg/kg) | ? | Farmakologiya i Toksikologiya Vol. 39, Pg. 53, 1976. |
rabbit | LDLo | subcutaneous | 531mg/kg (531mg/kg) | ? | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. |
rat | LD50 | intracrebral | 4800ug/kg (4.8mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Polish Journal of Pharmacology and Pharmacy. Vol. 26, Pg. 399, 1974. |
rat | LD50 | intraperitoneal | 514mg/kg (514mg/kg) | ? | Personal Communication from K.P. Petersen, DAK Labs., 59 Lergravsvej, DK-2300, Copenhagen, Demark, Dec. 22, 1977Vol. 22DEC1977, |
rat | LD50 | intratracheal | 205mg/kg (205mg/kg) | ? | "Spravochnik po Toksikologii i Gigienicheskim Normativam Vol. -, Pg. 157, 1999. |
rat | LD50 | oral | 526mg/kg (526mg/kg) | ? | Acta Pharmacologica et Toxicologica. Vol. 47, Pg. 351, 1980. |
rat | LD50 | subcutaneous | 499mg/kg (499mg/kg) | ? | Personal Communication from K.P. Petersen, DAK Labs., 59 Lergravsvej, DK-2300, Copenhagen, Demark, Dec. 22, 1977Vol. 22DEC1977, |